Abstract Treatment of breast cancer cells with a combination of the EGFR-tyrosine kinase inhibitor (EGFR-TKI) gefitinib and the anti-ErbB-2 monoclonal antibody trastuzumab results in a synergistic antitumor effect. In this study, we addressed the mechanisms involved in this phenomenon. The activation of signaling pathways and the expression of cell cycle regulatory proteins were studied in SK-Br-3 and BT-474 breast cancer cells, following treatment with EGFR and/or ErbB-2 inhibitors. Treatment with the gefitinib/trastuzumab combination produced, as compared with a single agent, a more prolonged blockade of AKT and MAPK activation, a more pronounced accumulation of cells in the G0/G1 phase of the cell cycle, a more significant increase in the levels of p27 kip1 and of hypophosphorylated pRb2, and a decrease in the levels of Cyclin D1 and survivin. Similar findings were observed with the EGFR/ErbB-2 inhibitor lapatinib. Gefitinib, trastuzumab, and their combination increased the stability of p27 kip1 , with the combination showing the highest effects. Blockade of both receptors with gefitinib/trastuzumab or lapatinib induced a significant increase in the levels of p27 kip1 mRNA and in the nuclear levels of the p27 kip1 transcription factor FKHRL-1. Inhibition of PI3K signaling also produced a significant raise in p27 kip1 mRNA. Finally, down-modulation of FKHRL-1 with siRNAs prevented the lapatinibinduced increase of p27 kip1 mRNA. The synergism deriving from EGFR and ErbB-2 blockade is mediated by several different alterations in the activation of signaling proteins and in the expression of cell cycle regulatory proteins, including transcriptional and posttranscriptional regulation of p27 kip1 expression.
Introduction
It has long been established that the epidermal growth factor receptor (EGFR, ErbB-1, HER1) and ErbB-2 (HER2, neu) cooperate in inducing oncogenic transformation. For example, simultaneous overexpression of both p185c-neu and EGFR was required to induce transformation in NIH:3T3 cells [1] . In addition, mammary tumors derived from transgenic mice engineered to overexpress neu also exhibited co-overexpression of endogenous EGFR [2] . Similarly, a synergistic interaction of the neu protooncogene and the EGFR ligand transforming growth factor-a (TGFa) in inducing transformation in the mammary epithelium of transgenic mice has also been demonstrated [3] . Finally, treatment of ErbB-2 transgenic mice with an EGFR-TKI such as gefitinib efficiently prevented the formation of mammary tumors [4] .
Coexpression of EGFR and ErbB-2 has been observed in 10-36% primary human breast carcinomas, and it is generally associated with a poor prognosis as compared with expression of a single receptor [5] [6] [7] . DiGiovanna et al. [8] found EGFR expression in only 15% of 807 invasive breast cancers. However, the majority of EGFR-positive tumors (87%) were found to coexpress ErbB-2. More importantly, almost all the tumors that expressed the phosphorylated form of ErbB-2, coexpressed EGFR, and expression of phosphorylated ErbB-2 or coexpression of ErbB-2 and EGFR was associated with the shortest survival in cancer patients. These data clearly establish a link in vivo between expression of EGFR and activation of ErbB-2 in breast cancer patients. In agreement with these findings, coexpression of EGFR, ErbB-2, and ErbB-3 was also found to have a negative synergistic effect on patient outcome, independent of tumor size or lymph node status [9] .
Different anti-EGFR agents, including the EGFR-TKI gefitinib (ZD1839, Iressa), have shown to inhibit the growth of human breast carcinoma cells [10] [11] [12] [13] [14] . We and other research groups have demonstrated that breast cancer cell lines with high levels of expression of ErbB-2 are more sensitive to gefitinib as compared with ErbB-2-negative cells [11] [12] [13] [14] . However, clinical studies of gefitinib in breast cancer resulted in a few clinical responses and in a disease control rate of approximately 10% [15] [16] [17] . ErbB-2-positive breast cancer patients enrolled in trials of gefitinib failed to respond, suggesting that ErbB-2-positive tumor cells might acquire resistance to anti-EGFR agents [17] [18] [19] . In this regard, Sergina et al. [20] have recently demonstrated that breast cancer cells that coexpress EGFR, ErbB-2, and ErbB-3 escape the activity of EGFR-TKIs through an ErbB-3/PI3K/AKT pathway. Interestingly, they found that ErbB-3 activation was dependent on ErbB-2, whose residual kinase activity was able to drive ErbB-3 phosphorylation. In addition, acquired resistance to antiErbB-2 agents can occur through different mechanisms including increased activation of EGFR signaling [21] , suggesting that a cross talk between these two receptors might limit the activity of target-based agents directed against either the EGFR or the ErbB-2 in breast cancer patients.
We and other groups have earlier demonstrated that a synergistic antitumor effect occurs when breast cancer cells that coexpress EGFR and ErbB-2 are treated with a combination of gefitinib and the anti-ErbB-2 monoclonal antibody trastuzumab [11] [12] [13] . In particular, we demonstrated that the two drugs have a strong synergism in breast cancer cells by using a wide range of concentrations of both drugs and isobolographic analysis [13] . Such combination failed to show significant activity in a phase I/II clinical trial [22] . However, patients enrolled in this trial were not selected for expression of the EGFR, since the aim of this study was to evaluate the ability of gefitinib to prevent the occurrence of resistance to trastuzumab in ErbB-2-positive patients. Contemporary targeting of both EGFR and ErbB-2 can be also accomplished by using tyrosine kinase inhibitors that block the activity of different ErbB-receptors. In this regard, lapatinib is a dual EGFR/ErbB-2 tyrosine kinase inhibitor that has been recently approved for treatment of ErbB-2 expressing patients [21] .
In this article, we investigated the molecular mechanisms involved in the synergism of combined blockade of EGFR and ErbB-2 by using either a combination of gefitinib and trastuzumab or the dual EGFR/ErbB-2 inhibitor lapatinib. In particular, the effects of blockade of EGFR and/or ErbB-2 on the activation of signal transduction pathways and on the expression of cell cycle regulatory proteins were assessed.
Materials and methods

Materials
Gefitinib was kindly provided by AstraZeneca (Macclesfield, UK); trastuzumab (Herceptin) was purchased from Roche (Milan, Italy); lapatinib was obtained from Glaxo Smith Kline; cycloheximide was purchased from Sigma (Saint Louis, Missouri, USA); U0126 and LY294002 were purchased from Promega (Madison, WI).
Cell culture
The human breast cancer cell lines SK-Br-3 and BT-474 were obtained from the American Type Culture Collection (Manassas, VA, USA) and were cultured as described earlier [13] .
Small interfering RNA ON-TARGET plus SMARTpool against human FKHRL-1 (containing four individual siRNA motifs: GCACAG AGUUGGAUGAAGU, GUACUCAACUAGUGCAAAC, CGAAUCAGCUGACGACAGU, UAACUUUGAUUCCC UCAUC) and control nontargeting siRNA were purchased from Dharmacon Inc. (Lafayette, CO). Transfections were performed using 50 nM siRNA and the INTERFERin TM siRNA transfection reagent (Polyplus transfection).
Protein extraction and western blot analysis Cells were seeded in 100 mm dishes (1 9 10 6 SK-Br-3 cells; 2 9 10 6 BT-474 cells) and treated at time 0 with gefitinib (2 lM SK-Br-3 cells; 1 lM BT-474 cells), trastuzumab (20 lg/ml), or lapatinib (140 nM). For experiments of protein stability, cells were also treated with 10 lM cycloheximide for 2, 4, and 8 h. Whole protein extraction and western blot analysis were performed as described earlier [13] . Nuclear or cytoplasmic proteins were differentially extracted by lysing cells in ice-cold hypotonic buffer (0.2% NP-40, 10 mM HEPES, pH 7.9, 1 mM EDTA, 60 mM KCl). Nuclei were separated through a 30% sucrose cushion and lysed in hypertonic buffer (250 mM Tris-HCl, pH 7.8, 60 mM KCl). Primary antibodies used for western blot analysis were: rabbit polyclonal anti-p27 kip1 , anti-cyclin D1, and anti-Sp1 (PEP 2) (Santa Cruz); rabbit monoclonal antiphospho-HER2/ErbB-2 (Tyr1221/1222) (6B12), rabbit polyclonal antiphospho-EGF Receptor (Tyr 1068), anti-p42/44 and -phospho-p42/ 44 (Thr202/Tyr204) MAPK, and anti-AKT and -phosphoAkt (Ser 473) (Cell Signaling); rabbit polyclonal antihuman survivin (R&D); mouse monoclonal antihuman Rb2 (BD Biosciences); rabbit polyclonal anti-FKHRL-1 (U.B.I.); mouse monoclonal antitubulin-a Ab-2 clone DM1A (Lab Vision Co. USA). Densitometric analysis of the blots was performed by using the NIH Image 1.62f software.
Flow cytometric analysis
Cells were trypsinized, washed two times with ice-cold PBS, and then resuspended on vortex in 1 ml PBS plus 3 ml ice-cold 95% EtOH. Then, cells were incubated in 1 ml of propidium iodide staining solution (50 lg/ml propidium iodide, 0.5 mg/ml RNase, 0.2% NP-40). After 30 min at room temperature in the dark, the DNA content was analyzed using a FACScan flow cytometer (Becton Dickinson, San Jose, CA). Cell cycle data analysis was performed by the CellFIT program (Becton Dickinson).
Real-time PCR
Total cellular RNA extraction and reverse transcriptase reaction were performed as described earlier [23] . Realtime PCR for p27 kip1 was carried out with a 7900HT ABI PRISM Instrument (Applied Biosystems) using the SybrGreen PCR Master Mix (Applied Biosystems) and the RT 2 qPCR Primer Assays SybrGreen Human CDKN1B (p27) and Human GAPDH (Superarray, Frederick, MD, USA). Relative quantification of p27 transcript was performed by using the DDCt method as described earlier [23] .
Results
We explored the molecular mechanisms involved in the synergism of the EGFR-TKI gefitinib and the anti-ErbB-2 humanized antibody trastuzumab in the breast cancer cell lines SK-Br-3 and BT-474, which overexpress both EGFR and ErbB-2. In these experiments, we used concentrations of gefitinib (1 or 2 lM) and trastuzumab (20 lg/ml) that have shown to produce a significant synergism in both breast cancer cell lines [13] . We and other groups have previously demonstrated that at the above-mentioned concentrations of gefitinib do not directly affect the kinase activity of ErbB-2 in live cells [11, 13] .
Effects of treatment with gefitinib and trastuzumab on the activation of ErbB receptors and MAPK and AKT signaling
In the preliminary experiments, we assessed the effects of treatment with gefitinib, trastuzumab, and the combination of the two drugs on the activation of both EGFR and ErbB-2. In agreement with previous findings, we found that the treatment with gefitinib reduced the activation of both EGFR and ErbB-2 in the SK-Br-3 and BT-474 breast cancer cell lines [10, 11, 13] (Supplementary Fig. 1 ). As reported earlier, trastuzumab treatment produced a reduction in the levels of activation of ErbB-2 that was more pronounced in BT-474 cells as compared with SK-Br-3 cells [24] . The effects of the combination of the two agents on the activation of the EGFR were comparable to gefitinib, whereas a more pronounced reduction in the levels of activation of ErbB-2 was found as compared with each single agent.
We have demonstrated earlier that the treatment with gefitinib and trastuzumab, alone or in combination, reduces the activation of intracellular transducers of growth factor signaling, such as p42/p44 MAP kinases (MAPK) and AKT in both breast carcinoma cell lines [13] . We hypothesized that the combination of the two drugs might lead to a more prolonged reduction of the activation of both signaling pathways. Therefore, we performed a time course experiment to evaluate the differences between treatment with a single agent and the combination of gefitinib and trastuzumab on the activation of these pathways. In these experiments, cells were treated once and proteins were extracted at the indicated times.
We found that the treatment of SK-Br-3 and BT-474 cells with gefitinib at concentrations of 2 and 1 lM, respectively, produced a significant reduction in the levels of activation of MAPK and AKT at 6 h from treatment. After 24 and 48 h, the levels of phosphorylation of both kinases gradually raised. In contrast, treatment with 20 lg/ml trastuzumab had little effect on MAPK activation in SKBr-3 cells, whereas it led to a gradual reduction of MAPK phosphorylation in the BT-474 cell line. In both cell lines, trastuzumab produced a significant reduction of AKT activation that reached a maximum at 6 or 24 h from treatment in BT-474 and SK-Br-3 cells, respectively. Combined treatment with gefitinib and trastuzumab produced a more significant and prolonged reduction of MAPK and AKT signaling in both breast cancer cell lines (Fig. 1) . Treatment with gefitinib, trastuzumab, or the combination had no effects on endogenous levels of p42/ p44 MAPK and AKT proteins in both cell lines (Fig. 1) .
Cell cycle distribution of breast cancer cells following treatment with gefitinib and trastuzumab
We analyzed the cell cycle distribution of the SK-Br-3 and BT-474 cell lines following treatment with gefitinib and trastuzumab, alone or in combination, at the above-mentioned concentrations for 24 and 48 h. The combination of the two drugs produced a more significant accumulation of cells in the G0/G1 phase of the cell cycle and reduction of cells in the S-phase, as compared with treatment with a single drug. Although such difference was evident after 24 h, it became more significant at 48 h of treatment ( Fig. 2 and data not shown) . In agreement with previous findings, a sub-G0/G1 peak, suggestive of apoptosis, was evident in the cells treated with the combination, but not with gefitinib or trastuzumab alone (Fig. 2) .
Effects of treatment with gefitinib and trastuzumab on cell cycle regulatory proteins in breast cancer cells Subsequently, using western blot analysis, we determined the expression of p27 kip1 in whole protein lysates, and in cytosolic and nuclear fractions from untreated and treated breast cancer cells. The combination of gefitinib plus trastuzumab produced a bigger increase in the levels of p27 kip1 in all the protein extracts as compared with treatment with a single drug (Fig. 3 and data not shown) . No significant effects were observed on p21 cip1 expression (data not shown). Treatment of SK-Br-3 and BT-474 cells with gefitinib and trastuzumab also affected the expression of other proteins involved in cell cycle progression and apoptosis. In particular, a significant reduction of cyclin D1 and survivin levels and an increase of hypophosphorylated forms of p130Rb2 (pRb2) were observed in treated cells as compared with untreated cells, with the combination of drugs having a more pronounced effect at 48 h of treatment (Fig. 3) . These experiments were repeated three times, and we always observed a more pronounced effect of the combination as compared with each single agent.
Molecular mechanisms of p27
kip1 induction: protein stabilization and increase of p27 kip1 mRNA
In order to investigate the mechanisms by which treatment with gefitinib and trastuzumab leads to the increase of p27 kip1 expression, we evaluated the effects of these drugs on p27 kip1 protein stability. We exposed SK-Br-3 cells to cycloheximide, an inhibitor of protein synthesis, following 48 h of treatment with the different drugs. All the treatments increased the stability of p27 kip1 protein. However, the combination showed higher effects as compared to treatments with single drugs, and gefitinib had higher effects than trastuzumab (gefitinib plus trastuzumab [ gefitinib [ trastuzumab) (Fig. 4) . Similar findings were obtained in BT-474 cells in which trastuzumab and gefitinib produced analogous effects on p27 kip1 protein stability, whereas the combination showed higher effects as compared with each drug alone ( Supplementary  Fig. 2) .
We next analyzed the effects of EGFR and/or ErbB-2 blockade on the expression of p27 kip1 mRNA by using quantitative Real-time PCR. A significant increase in the levels of p27 kip1 mRNA was found in SK-Br-3 cells treated with gefitinib plus trastuzumab for 48 h as compared with untreated cells or cells treated with a single drug (Fig. 5b) . Similar findings were obtained in BT-474 cells (Fig. 5c ).
Analysis of the nuclear fraction from SK-Br-3 and BT-474 cells revealed that treatment with the combination produced a more pronounced increase in the nuclear levels of the p27 kip1 transcription factor FKHRL-1 (forkhead transcription factor in rhabdomyosarcoma-like 1, FOXO3a) as compared with gefitinib or trastuzumab alone (Fig. 5a) . AKT phosphorylates FKHRL-1, thus, prevented its migration to the nucleus [25] . In agreement with these findings, blockade of AKT signaling with the PI3K inhibitor LY294002 produced a significant increase in the levels of p27 kip1 mRNA in SK-Br-3 cells (Fig. 5d) . In contrast, treatment with the MEK inhibitor U0126 had no significant effects on p27 kip1 mRNA levels (Fig. 5d) . Effects of treatment with lapatinib on cell cycle regulatory proteins in SK-Br-3 cells
Subsequently, we evaluated the effects of lapatinib on the above-described mechanisms. Treatment of SK-Br-3 cells with lapatinib produced a significant increase in the levels of p27 kip1 and of hypophosphorylated pRb2, and a significant decrease in the levels of cyclin D1 and survivin, similar to the effects of the gefitinib/trastuzumab combination (Fig. 6 ).
More importantly, an increase in p27 kip1 mRNA (Fig. 7a) and in the nuclear levels of FKHRL-1 (Fig. 7b) was also observed following the treatment of SK-Br-3 cells with lapatinib. Therefore, we examined the effect of siR-NA-mediated FKHRL-1 silencing on p27 kip1 mRNA Fig. 7c , transfection of SK-Br-3 cells with 50 nM of specific FKHRL-1 siRNAs produced a significant reduction of FKHRL-1 protein expression. The FKHRL-1 siRNAs, but not control nontargeting siRNA, significantly reduced the ability of lapatinib to induce an increase of p27 kip1 mRNA in SK-Br-3 cells (Fig. 7d) . A slight effect of the FKHRL-1 siRNAs on the basal levels of p27 kip1 mRNA in untreated cells was also observed. These results demonstrate that lapatinib-induced p27 kip1 mRNA expression is mediated by FKHRL-1.
Discussion
Breast cancer cells that overexpress ErbB-2 are dependent on the activation of this oncogene for their proliferation and survival and are significantly inhibited by agents directed against ErbB-2. Although spontaneous activation of ErbB-2 might occur in cells that overexpress the receptor, transactivation by other receptors of the same family such as EGFR and ErbB-3 might lead to its phosphorylation [26] . Therefore, it is conceivable that this phenomenon might play a role in determining the sensitivity/resistance to anti-ErbB-2 agents. In this regard, it has been shown that resistance to trastuzumab might involve the activation of a TGFa/EGFR autocrine loop [27] . We and others have demonstrated that gefitinib and trastuzumab have a synergistic antitumor effect in breast cancer cells that express both receptors. Synergism of anti-EGFR and anti-ErbB-2 agents has also been demonstrated in cells derived from tumors of different histologic type, such as ovarian, non-small cell lung and pancreatic carcinomas [28] [29] [30] . Our study is the first to address the mechanisms involved in the synergism of contemporary blockade of EGFR and ErbB-2 in breast cancer cells. In particular, we have shown that blockade of both tyrosine kinases causes a prolonged inhibition of MAPK and AKT activation as compared with inhibition of a single receptor. Both these pathways are involved in the intrinsic and acquired resistance of breast cancer cells to anti-EGFR and anti-ErbB-2 drugs [26, 31, 32] . Interestingly, our findings show that following the treatment with trastuzumab, an increase in the levels of activation of MAPK is observed (Fig. 1) . This phenomenon might represent an attempt of tumor cells to escape the activity of the drug that mainly blocks the ErbB-2/AKT pathway. The use of a combination of drugs targeting both the EGFR and ErbB-2 prevented trastuzumabinduced MAPK activation, which might, therefore, involve the EGFR. In addition, combined blockade had a synergistic effect on the expression of different proteins that regulate cell cycle progression, such as p27 kip1 , cyclin D1 and pRb2, and survival (survivin) and resulted in a more pronounced G0/G1 block and induction of apoptosis as compared with inhibition of a single pathway.
Regulation of p27 kip1 expression and/or intracellular localization is one of the principal mechanisms through which anti-EGFR and anti-ErbB-2 drugs block cell cycle progression in cancer cells [33] [34] [35] [36] [37] . Several studies have demonstrated that p27 kip1 expression is mainly regulated at post-transcriptional level by protein stabilization [38] [39] [40] [41] [42] . However, we found that when both EGFR and ErbB-2 are blocked by using either the combination of trastuzumab plus gefitinib or the dual inhibitor lapatinib, a significant increase in the levels of p27 kip1 mRNA is also observed. This phenomenon was found to be mediated by FKHRL-1, a member of the Forkhead family of transcription factor [43] , which is one of the principal regulators of p27 kip1 mRNA expression. FKHRL-1 is also an AKT substrate: AKT inactivates FKHRL-1 by phosphorylation that produces a retention of the transcription factor into the cytoplasm [25] . The finding that FKHRL-1 nuclear levels increased only in cells treated with the combination of the two drugs suggests that a near full inhibition of AKT activation is required to cause an increase of p27 kip1 gene transcription. These results also highlight that the mechanism of action of combinations of biologic agents might significantly differ from the activity of a single drug, by inducing profound biochemical modifications in the target cells.
The main question that needs to be addressed is whether contemporary blockade of EGFR and ErbB-2 might result in a significant activity in breast cancer patients. Contrasting results have been obtained in clinical trials of combinations of anti-ErbB-2 and anti-EGFR agents. The combination of gefitinib and trastuzumab failed to show significant activity in a phase I/II clinical trial in which patients were not selected for the expression of the EGFR [22] . In fact, this study aimed to address the ability of gefitinib to prevent the occurrence of resistance to trastuzumab, following preclinical and clinical observations suggesting a potential role of TGFa signaling in the acquired resistance to trastuzumab. Post study evaluation of EGFR expression revealed that this receptor was expressed only in 6/28 patients. In addition, a low dose of gefitinib (250 mg/die corresponding to one-third of the maximum tolerated dose) was used in this trial, due to the significant toxicity that was observed in patients treated with full dose trastuzumab and 500 mg/die gefitinib in the Phase I part of the study.
Overall, a number of studies have clearly demonstrated that lapatinib is active only in patients that overexpress ErbB-2. A recent report confirmed that the response to lapatinib in breast cancer patients correlates with ErbB-2 status (amplified versus nonamplified), but not with EGFR expression [44] . Patients with ErbB-2 amplification benefited of lapatinib treatment regardless of EGFR expression. However, the levels of activation of the EGFR were not assessed in this study. Therefore, the potential role of EGFR in increasing ErbB-2 activation in selected patients was not explored.
Interestingly, the combination of erlotinib and trastuzumab showed preliminary clinical activity in ErbB-2 overexpressing breast cancer patients that were not previously treated with trastuzumab [45] . In this study, the dose of erlotinib (100 or 150 mg/die, corresponding to twothirds or full maximum tolerated dose, respectively) was adjusted on individual patient tolerability. However, very few patients were enrolled in this study, which was closed early due to the difficulty to enroll patients following the availability of lapatinib.
Taken together, these data suggest that the specific drugs used in the different trials might account in part for the diverse clinical efficacy of such combinations. More importantly, the levels of activation rather than the expression of the target receptors might result more informative for an appropriate selection of patients that might benefit of this approach. Indeed, no correlation between the levels of expression of EGFR and activity of anti-EGFR agents has been found in different tumor types, including lung and colon carcinomas [26] . Interestingly, increasing evidence suggests that the levels of expression of EGFR ligands correlate with activity of the anti-EGFR monoclonal antibody cetuximab in metastatic colorectal cancer patients [46] . High levels of ligands might represent an indirect marker of the levels of activation of EGFR or other ErbB receptors.
In conclusion, contemporary blockade of EGFR and ErbB-2 receptors in breast cancer cells is able to produce a significant arrest of cell proliferation, together with changes in the expression of factors that regulate cell cycle progression such as p27 kip1 . Although preliminary studies failed to demonstrate the clinical efficacy of this strategy in women affected by breast carcinoma, these results suggest that blockade of EGFR and ErbB-2 might represent a novel and effective therapeutic approach in selected patients.
